术后无功能性垂体腺瘤伽玛刀手术后垂体功能减退
该研究回顾了2001至2015年间971例无功能性垂体腺瘤经蝶手术患者中76例(7.8%)术后接受伽玛刀手术者的长期垂体功能试验数据,发现53例可评估患者中13例(24.5%)发生垂体功能减退,术前激素正常者发生率(41.7%,10/24)高于术前激素异常者(10.3%,3/29;p=0.024),并提出了垂体柄和正常腺体辐射剂量预测界值。
要点
- 术后伽玛刀手术患者平均随访53.5±35.5个月,肿瘤控制率96%。
- 术前激素正常者伽玛刀后垂体功能减退发生率41.7%(10/24),高于术前异常者的10.3%(3/29;p=0.024)。
- 肿瘤体积、肿瘤与垂体柄距离、垂体柄剂量及正常腺体剂量为伽玛刀后垂体功能减退的预测因素(p<0.05)。
核心结论
- 作者分析了经蝶手术后接受伽玛刀手术的无功能性垂体腺瘤患者的长期垂体功能试验数据。
- 作者提出了预防伽玛刀后垂体功能减退的垂体柄和正常腺体辐射剂量界值。
研究设计与样本
- 回顾性分析2001至2015年间971例经蝶手术治疗的无功能性垂体腺瘤患者,其中76例(7.8%)术后接受伽玛刀手术。
- 76例患者均在伽玛刀手术前后接受联合垂体功能试验,分析伽玛刀前相关因素、伽玛刀相关因素及临床结局。
- 76例中23例被排除(22例伽玛刀前全垂体功能减退,1例失访),剩余53例纳入分析。
主要发现
- 971例中797例全切除、174例次全切除;全切除患者25例(3.1%)和次全切除患者51例(29.3%)接受伽玛刀手术。
- 伽玛刀后平均随访53.5±35.5个月,肿瘤控制率96%。
- 53例可评估患者中13例(24.5%)发生垂体功能减退。
- 术前激素正常者伽玛刀后垂体功能减退发生率41.7%(10/24),高于术前激素异常者的10.3%(3/29;p=0.024)。
- 靶肿瘤体积(4.7±3.9 cm3)、肿瘤与垂体柄距离(2.0±2.2 mm)、垂体柄剂量(界值:平均剂量7.56 Gy,最大剂量12.3 Gy)及正常腺体剂量(界值:最大剂量13.9 Gy,最小剂量5.25 Gy)为伽玛刀后垂体功能减退的预测因素(p<0.05)。
关键数值与推荐
- 垂体柄剂量界值:平均剂量7.56 Gy,最大剂量12.3 Gy。
- 正常腺体剂量界值:最大剂量13.9 Gy,最小剂量5.25 Gy。
临床怎么用
- 作者提出垂体柄和正常腺体辐射剂量界值以预防伽玛刀后垂体功能减退。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVEThis study investigated long-term follow-up data on the combined pituitary function test (CPFT) in patients who had undergone transsphenoidal surgery (TSS) for nonfunctioning pituitary adenoma (NFPA) to determine the clinical parameters indicative of hypopituitarism following postoperative Gamma Knife surgery (GKS).METHODSBetween 2001 and 2015, a total of 971 NFPA patients underwent TSS, and 76 of them (7.8%) underwent postoperative GKS. All 76 patients were evaluated with a CPFT before and after GKS. The hormonal states were analyzed based on the following parameters: relevant factors before GKS (age, sex, extent of resection, pre-GKS hormonal states, time interval between TSS and GKS), GKS-related factors (tumor volume; radiation dose to tumor, pituitary stalk, and normal gland; distance between tumor and stalk), and clinical outcomes (tumor control rate, changes in hormonal states, need for hormone-related medication due to hormonal changes).RESULTSOf the 971 NFPA patients, 797 had gross-total resection (GTR) and 174 had subtotal resection (STR). Twenty-five GTR patients (3.1%) and 51 STR patients (29.3%) underwent GKS. The average follow-up period after GKS was 53.5 ± 35.5 months, and the tumor control rate was 96%. Of the 76 patients who underwent GKS, 23 were excluded due to pre-GKS panhypopituitarism (22) or loss to follow-up (1). Hypopituitarism developed in 13 (24.5%) of the remaining 53 patients after GKS. A higher incidence of post-GKS hypopituitarism occurred in the patients with normal pre-GKS hormonal states (41.7%, 10/24) than in the patients with abnormal pre-GKS hormonal states (10.3%, 3/29; p = 0.024). Target tumor volume (4.7 ± 3.9 cm3), distance between tumor and pituitary stalk (2.0 ± 2.2 mm), stalk dose (cutoffs: mean dose 7.56 Gy, maximal dose 12.3 Gy), and normal gland dose (cutoffs: maximal dose 13.9 Gy, minimal dose 5.25 Gy) were factors predictive of post-GKS hypopituitarism (p < 0.05).CONCLUSIONSThis study analyzed the long-term follow-up CPFT data on hormonal changes in NFPA patients who underwent GKS after TSS. The authors propose a cutoff value for the radiation dose to the pituitary stalk and normal gland for the prevention of post-GKS hypopituitarism.
引用
- Oh JW, Sung KS, Moon JH, et al. Hypopituitarism after Gamma Knife surgery for postoperative nonfunctioning pituitary adenoma. J Neurosurg. 2018. PMID: 30544293. doi:10.3171/2018.7.GKS181589
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。